Population Pharmacokinetics of Levetiracetam and Dosing Evaluation in Critically Ill Patients with Normal or Augmented Renal Function
dc.contributor.author | Bilbao-Meseguer, Idoia | |
dc.contributor.author | Barrasa González, Helena | |
dc.contributor.author | Asín-Prieto, Eduardo | |
dc.contributor.author | Alarcia Lacalle, Ana | |
dc.contributor.author | Rodríguez Gascón, Alicia | |
dc.contributor.author | Maynar, Javier | |
dc.contributor.author | Sánchez-Izquierdo, José Ángel | |
dc.contributor.author | Balziskueta Flórez, Goiatz | |
dc.contributor.author | Sánchez-Bayton Griffith, María | |
dc.contributor.author | Quilez Trasobares, Nerea | |
dc.contributor.author | Solinís Aspiazu, María Ángeles ![]() | |
dc.contributor.author | Isla Ruiz, Arantxazu ![]() | |
dc.date.accessioned | 2021-10-27T08:46:42Z | |
dc.date.available | 2021-10-27T08:46:42Z | |
dc.date.issued | 2021-10-15 | |
dc.identifier.citation | Pharmaceutics 13(10) : (2021) // Article ID 1690 | es_ES |
dc.identifier.issn | 1999-4923 | |
dc.identifier.uri | http://hdl.handle.net/10810/53642 | |
dc.description.abstract | Levetiracetam is a broad-spectrum antiepileptic drug commonly used in intensive care units (ICUs). The objective of this study is to evaluate the adequacy of levetiracetam dosing in patients with normal or augmented renal clearance (ARC) admitted to the ICU by population modelling and simulation. A multicentre prospective study including twenty-seven critically ill patients with urinary creatinine clearance (CrCl) > 50 mL/min and treated with levetiracetam was developed. Levetiracetam plasma concentrations were best described by a two-compartment model. The parameter estimates and relative standard errors (%) were clearance (CL) 3.5 L/h (9%), central volume of distribution (V1) 20.7 L (18%), intercompartmental clearance 31.9 L/h (22%), and peripheral volume of distribution 33.5 L (13%). Interindividual variability estimates were, for the CL, 32.7% (21%) and, for V1, 56.1% (29%). The CrCl showed significant influence over CL. Simulations showed that the administration of at least 500 mg every 8 h or 1000 mg every 12 h are needed in patients with normal renal function. Higher doses (1500 or 2000 mg, every 8 h) are needed in patients with ARC. Critically ill patients with normal or ARC treated with levetiracetam could be at high risk of being underdosed. | es_ES |
dc.description.sponsorship | This research was funded by Department of Education of the Basque Government, grant number PIBA 2019-57; and by the University of the Basque Country UPV/EHU, grant number GIU20/048. A.A.-L. thanks the University of the Basque Country UPV/EHU for her research grant, number PIFG19/23. | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | MDPI | es_ES |
dc.rights | info:eu-repo/semantics/openAccess | es_ES |
dc.rights.uri | http://creativecommons.org/licenses/by/3.0/es/ | |
dc.subject | levetiracetam | es_ES |
dc.subject | augmented renal clearance | es_ES |
dc.subject | intensive care | es_ES |
dc.subject | critically ill patients | es_ES |
dc.subject | population pharmacokinetic | es_ES |
dc.subject | modelling | es_ES |
dc.subject | Monte Carlo simulations | es_ES |
dc.subject | seizure | es_ES |
dc.title | Population Pharmacokinetics of Levetiracetam and Dosing Evaluation in Critically Ill Patients with Normal or Augmented Renal Function | es_ES |
dc.type | info:eu-repo/semantics/article | es_ES |
dc.date.updated | 2021-10-22T13:56:00Z | |
dc.rights.holder | 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). | es_ES |
dc.relation.publisherversion | https://www.mdpi.com/1999-4923/13/10/1690/htm | es_ES |
dc.identifier.doi | 10.3390/pharmaceutics13101690 | |
dc.departamentoes | Farmacia y ciencias de los alimentos | |
dc.departamentoes | Medicina | |
dc.departamentoeu | Farmazia eta elikagaien zientziak | |
dc.departamentoeu | Medikuntza |
Files in this item
This item appears in the following Collection(s)
Except where otherwise noted, this item's license is described as 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).